文献速递基础与转化研究临床试验与 GCP

口服或鼻内递送的5型腺病毒SARS-CoV-2疫苗在仓鼠模型中减轻疾病严重程度并减少传播

Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model.
PubMed 文献 · Sci Transl Med · 2022-08-17

研究开发了表达刺突蛋白的口服5型腺病毒载体SARS-CoV-2疫苗候选,仓鼠经口或鼻内接种后产生强效交叉反应抗体;攻毒后口鼻接种组鼻和肺病毒RNA及感染性病毒减少、肺病理减轻;黏膜接种还降低空气传播。同一平台在1期临床试验(NCT04563702)中诱导黏膜交叉反应性IgA应答。

要点

  • 口服或鼻内接种5型腺病毒载体SARS-CoV-2疫苗的仓鼠产生强效交叉反应抗体。
  • 攻毒后口鼻接种组鼻和肺病毒RNA及感染性病毒减少,肺病理减轻。
  • 黏膜接种可能减少SARS-CoV-2空气传播,1期试验中该平台诱导黏膜IgA应答。

核心结论

  • 黏膜免疫是减轻SARS-CoV-2疾病和空气传播的可行策略。

研究设计与样本

  • 仓鼠模型:口服或鼻内接种表达刺突蛋白的5型腺病毒载体SARS-CoV-2疫苗候选,随后用SARS-CoV-2攻毒。
  • 单向气流舱暴露实验:未接种仓鼠暴露于黏膜接种且感染SARS-CoV-2的仓鼠。
  • 1期临床试验(NCT04563702):同一平台编码刺突和核衣壳蛋白。

主要发现

  • 口服或鼻内接种的仓鼠与模拟接种仓鼠相比,攻毒后鼻和肺中病毒RNA及感染性病毒减少,肺病理减轻。
  • 单向气流舱中暴露于黏膜接种感染仓鼠的未接种仓鼠,鼻拭子病毒RNA低于对照动物,临床症状更少。
  • 1期临床试验中,编码刺突和核衣壳蛋白的同一平台诱导黏膜交叉反应性SARS-CoV-2特异性IgA应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transmission-blocking strategies that slow the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and protect against coronavirus disease 2019 (COVID-19) are needed. We have developed an orally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine candidate that expresses the spike protein. Here, we demonstrated that hamsters vaccinated by the oral or intranasal route had robust and cross-reactive antibody responses. We then induced a postvaccination infection by inoculating vaccinated hamsters with SARS-CoV-2. Orally or intranasally vaccinated hamsters had decreased viral RNA and infectious virus in the nose and lungs and experienced less lung pathology compared to mock-vaccinated hamsters after SARS-CoV-2 challenge. Naïve hamsters exposed in a unidirectional air flow chamber to mucosally vaccinated, SARS-CoV-2-infected hamsters also had lower nasal swab viral RNA and exhibited fewer clinical symptoms than control animals, suggesting that the mucosal route reduced viral transmission. The same platform encoding the SARS-CoV-2 spike and nucleocapsid proteins elicited mucosal cross-reactive SARS-CoV-2-specific IgA responses in a phase 1 clinical trial (NCT04563702). Our data demonstrate that mucosal immunization is a viable strategy to decrease SARS-CoV-2 disease and airborne transmission.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Langel SN, Johnson S, Martinez CI, et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci Transl Med. 2022. PMID: 35511920. doi:10.1126/scitranslmed.abn6868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。